FDA
-
-
-
-
-
-
-
Ziopharm Oncology to Participate in September Investor Conferences
-
-
-
-
-
-
-
Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
-
-
-
-
-
-
-
Ziopharm Details Actions in Response to Shareholder Feedback
-
-
-
-
-
-
-
Ziopharm Oncology Appoints Mary Thistle to Board of Directors
-
-
-
-
-
-
-
Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG
-
-
-
-
-
-
-
Ziopharm Oncology (ZIOP) Reports First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for Treatment of Pediatric Brain Tumors
-
-
-
-
-
-
-
Ziopharm Oncology (ZIOP) announces Dr. David Mauney stepping down as President
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

